Revenue increased 13% to $49.6 billion
GAAP1 operating earnings were $137 million, GAAP diluted EPS were $0.40
Non-GAAP operating earnings decreased 20% to $423 million due to a decline in Medical segment profit, partially offset by an increase in Pharmaceutical segment profit; non-GAAP diluted EPS decreased 7% to $1.20
Company reaffirmed fiscal year 2023 non-GAAP EPS guidance
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.